Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
                
   
Jun Luo, Ph.D. Jun Luo, Ph.D.
Associate Professor of Urology
Johns Hopkins Medical Institutions

Email:jluo1@jhmi.edu

Dr. Jun Luo is a cell and molecular biologist by training with a broad background in prostate tumor biology, genomics, and genetics. He received his Ph.D. in Anatomy and Cell Biology in 1999. His Ph.D. thesis work focused on the role of cell-cell adhesion mediated by E-cadherin using the Dunning prostate cancer invasion model (Mentored by Dr. Mary J.C. Hendrix at the University of Iowa). He joined the Brady Urological Institute first as a postdoctoral fellow with Dr. William B. Isaacs. While a fellow (1999-2002) he was also a Guest Researcher at the National Human Genome Research Institute (NHGRI). Dr. Luo conducted one of the first high-density expression microarray studies on prostate cancer during this period. This study led to the discovery of a highly sensitive and specific prostate cancer tissue marker named AMACR, which has since been widely adopted as an ancillary tool in Surgical Pathology.

Dr. Luo joined the faculty at Brady in 2002. Research efforts in his laboratory continue to focus on the problem of prostate cancer through discovery, development, and clinical implementation of molecular tools for diagnosis, prognosis, and therapeutic prediction. The guiding concept for his research is that the clinical course of cancer progression is determined, and also accompanied, by dynamic interactions among genetic, epigenetic, and environmental factors that are ultimately manifested in the transcriptional phenotype. Dr. Luo employs cutting-edge technologies to investigate the prostate tumor transcriptional phenotype. Through a network of collaborators, Dr. Luo uses new knowledge gained from these studies as the basis for developing precision tools and molecular markers pertaining to prostate cancer management in a variety of clinical settings.

His main research interests are:

  1. Androgen receptor splice variants in contemporary clinical care of men with castration-resistant prostate cancer.
  2. Genomic profiles underlying natural history of prostate cancer progression and disease disparity by geographical ancestry.
  3. RNA sequencing technologies.
  4. Circulating tumor cells.

EDUCATION


1986-1990   B.S. Nanjing University  Zoology
1995-1999   Ph.D. University of Iowa  Anatomy and Cell Biology
1999-2002   Post-doc Johns Hopkins University  Oncogenomics

PUBLICATIONS

  1. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014;371(11):1028-38. Epub 2014/09/04. doi: 10.1056/NEJMoa1315815. PubMed PMID: 25184630.
  2.  
  3. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2014. Epub 2014/05/20. doi: 10.1038/onc.2014.115. PubMed PMID: 24837363.
  4.  
  5.  Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormones & cancer. 2014;5(5):265-73. Epub 2014/07/23. doi: 10.1007/s12672-014-0190-1. PubMed PMID: 25048254; PubMed Central PMCID: PMC4167475.
  6.  
  7.  Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of cellular biochemistry. 2014;115(9):1505-15. Epub 2014/03/08. doi: 10.1002/jcb.24805. PubMed PMID: 24604720.
  8.  
  9.  Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science translational medicine. 2013;5(169):169ra10. Epub 2013/01/25. doi: 10.1126/scitranslmed.3005211. PubMed PMID: 23345608; PubMed Central PMCID: PMC3577373.
  10.  
  11.  Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. European urology. 2013;64(4):567-76. Epub 2013/06/14. doi: 10.1016/j.eururo.2013.05.029. PubMed PMID: 23759327.
  12.  
  13.  Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Bjork P, Olsson A, Bjork A, Leanderson T. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer research. 2013;73(4):1386-99. Epub 2012/11/15. doi: 10.1158/0008-5472.CAN-12-2730. PubMed PMID: 23149916; PubMed Central PMCID: PMC3578133.
  14.  
  15.  Lu C, Luo J. Decoding the androgen receptor splice variants. Translational Andrology and Urology. 2013;2(3):178-86.
  16.  
  17.  Luo J, Pienta KJ. Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. European urology. 2013;64(2):339-40. Epub 2013/07/09. doi: 10.1016/j.eururo.2013.05.012. PubMed PMID: 23830228.
  18.  
  19.  Plymate SR, Luo J. The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer.  Androgen-Responsive Genes in Prostate Cancer: Springer; 2013. p. 201-13.
  20.  
  21.  Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, Kulkarni P. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer research. 2013;73(13):4123-33. Epub 2013/05/15. doi: 10.1158/0008-5472.CAN-12-1343. PubMed PMID: 23667174.
  22.  
  23.  Dunn TA, Fedor HL, De Marzo AM, Luo J. Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian journal of andrology. 2012;14(3):385-92. Epub 2012/02/07. doi: 10.1038/aja.2011.147. PubMed PMID: 22306912; PubMed Central PMCID: PMC3433951.
  24.  
  25.  Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer research. 2012;72(14):3457-62. Epub 2012/06/20. doi: 10.1158/0008-5472.CAN-11-3892. PubMed PMID: 22710436; PubMed Central PMCID: PMC3415705.
  26.  
  27.  Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate. 2012;72(14):1491-505. Epub 2012/03/08. doi: 10.1002/pros.22504. PubMed PMID: 22396319; PubMed Central PMCID: PMC3374010.
  28.  
  29.  Li J, Zhang ZH, Yin CJ, Pavlovich C, Luo J, Getzenberg R, Zhang W. Effect of surgical procedures on prostate tumor gene expression profiles. Asian journal of andrology. 2012;14(5):708-14. Epub 2012/08/07. doi: 10.1038/aja.2012.54. PubMed PMID: 22864281; PubMed Central PMCID: PMC3734993.
  30.  
  31.  Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Gronberg H, Isaacs WB, Xu J. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2012;31(35):3939-48. Epub 2011/12/06. doi: 10.1038/onc.2011.554. PubMed PMID: 22139082; PubMed Central PMCID: PMC3667348.
  32.  
  33. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PloS one. 2012;7(3):e32832. Epub 2012/04/06. doi: 10.1371/journal.pone.0032832. PubMed PMID: 22479342; PubMed Central PMCID: PMC3316551.
  34.  
  35. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. The Prostate. 2011;71(15):1656-67. Epub 2011/03/30. doi: 10.1002/pros.21382. PubMed PMID: 21446008; PubMed Central PMCID: PMC3360954.
  36.  
  37. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH. Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. Journal of translational medicine. 2011;9:153. Epub 2011/09/16. doi: 10.1186/1479-5876-9-153. PubMed PMID: 21917134; PubMed Central PMCID: PMC3184272.
  38.  
  39. Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W, Wang Q. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer research. 2011;71(21):6738-48. Epub 2011/09/09. doi: 10.1158/0008-5472.CAN-11-1882. PubMed PMID: 21900400; PubMed Central PMCID: PMC4081454.
  40.  
  41. Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert review of endocrinology & metabolism. 2010;5(5):753-64. Epub 2011/02/15. doi: 10.1586/eem.10.49. PubMed PMID: 21318111; PubMed Central PMCID: PMC3035007.
  42.  
  43. Luo J, Chen Y. Use of Expression Microarrays in Cancer Research.  Modern Molecular Biology: Springer; 2010. p. 67-85.
  44.  
  45. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. The Prostate. 2010;70(16):1778-87. Epub 2010/06/29. doi: 10.1002/pros.21214. PubMed PMID: 20583133.
  46.  
  47. Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim ST, Zheng SL, Xu J, Isaacs WB, Chang BL. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. The Prostate. 2009;69(3):327-35. Epub 2008/11/28. doi: 10.1002/pros.20882. PubMed PMID: 19035483; PubMed Central PMCID: PMC2795318.
  48.  
  49. Dunn TA, Fedor H, Isaacs WB, De Marzo AM, Luo J. Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. The Prostate. 2009;69(2):214-8. Epub 2008/11/01. doi: 10.1002/pros.20863. PubMed PMID: 18973134; PubMed Central PMCID: PMC2612089.
  50.  
  51. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. The Prostate. 2009;69(6):603-9. Epub 2009/01/07. doi: 10.1002/pros.20910. PubMed PMID: 19125417; PubMed Central PMCID: PMC3170854.
  52.  
  53. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer research. 2009;69(1):16-22. Epub 2009/01/02. doi: 10.1158/0008-5472.CAN-08-2764. PubMed PMID: 19117982; PubMed Central PMCID: PMC2614301.
  54.  
  55. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature medicine. 2009;15(5):559-65. Epub 2009/04/14. doi: 10.1038/nm.1944. PubMed PMID: 19363497; PubMed Central PMCID: PMC2839160.
  56.  
  57. Luo J. Explaining hormone-deprivation therapy failure in prostate cancer patients2009.
  58.  
  59. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer research. 2009;69(18):7165-9. Epub 2009/09/10. doi: 10.1158/0008-5472.CAN-09-1448. PubMed PMID: 19738047; PubMed Central PMCID: PMC2861586.
  60.  
  61. Apostolou A, Shen Y, Liang Y, Luo J, Fang S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Experimental cell research. 2008;314(13):2454-67. Epub 2008/06/20. doi: 10.1016/j.yexcr.2008.05.001. PubMed PMID: 18561914.
  62.  
  63. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008;21(9):1156-67. Epub 2008/06/24. doi: 10.1038/modpathol.2008.111. PubMed PMID: 18567993; PubMed Central PMCID: PMC3170853.
  64.  
  65. Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. The Prostate. 2008;68(13):1387-95. Epub 2008/06/11. doi: 10.1002/pros.20806. PubMed PMID: 18543251; PubMed Central PMCID: PMC4124602.
  66.  
  67. Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J. A novel role of myosin VI in human prostate cancer. The American journal of pathology. 2006;169(5):1843-54. Epub 2006/10/31. doi: 10.2353/ajpath.2006.060316. PubMed PMID: 17071605; PubMed Central PMCID: PMC1780223.
  68.  
  69. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G. Prognostic relevance of AGR2 expression in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(6):1728-34. Epub 2006/03/23. doi: 10.1158/1078-0432.CCR-05-2057. PubMed PMID: 16551856.
  70.  
  71. Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. The Prostate. 2005;64(1):67-74. Epub 2005/01/15. doi: 10.1002/pros.20215. PubMed PMID: 15651028.
  72.  
  73. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. The Prostate. 2005;63(4):316-23. Epub 2004/12/16. doi: 10.1002/pros.20177. PubMed PMID: 15599942.
  74.  
  75. Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB. Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. Cancer research. 2004;64(7):2523-33. Epub 2004/04/03. PubMed PMID: 15059908.
  76.  
  77. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. The Prostate. 2004;61(3):215-27. Epub 2004/09/16. doi: 10.1002/pros.20095. PubMed PMID: 15368473; PubMed Central PMCID: PMC3715040.
  78.  
  79. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. The Journal of urology. 2004;172(4 Pt 1):1501-3. Epub 2004/09/17. PubMed PMID: 15371879.
  80.  
  81. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology. 2003;62(5 Suppl 1):55-62. Epub 2003/11/11. PubMed PMID: 14607218.
  82.  
  83. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. The Prostate. 2003;57(2):134-9. Epub 2003/09/02. doi: 10.1002/pros.10284. PubMed PMID: 12949937.
  84.  
  85. Luo J, Isaacs WB, Trent JM, Duggan DJ. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer investigation. 2003;21(6):937-49. Epub 2004/01/23. PubMed PMID: 14735697.
  86.  
  87. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. The American journal of surgical pathology. 2003;27(8):1128-33. Epub 2003/07/29. PubMed PMID: 12883245.
  88.  
  89. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer research. 2003;63(21):7365-76. Epub 2003/11/13. PubMed PMID: 14612535.
  90.  
  91. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. The Prostate. 2002;51(3):189-200. Epub 2002/04/23. doi: 10.1002/pros.10087. PubMed PMID: 11967953.
  92.  
  93. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer research. 2002;62(8):2220-6. Epub 2002/04/17. PubMed PMID: 11956072.
  94.  
  95. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer research. 2001;61(12):4683-8. Epub 2001/06/19. PubMed PMID: 11406537.
  96.  
  97. Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer research. 1999;59(15):3552-6. Epub 1999/08/14. PubMed PMID: 10446959.
  98.  
  99. Sharma N, Luo J, Kirschmann DA, O'Malley Y, Robbins ME, Akporiaye ET, Lubaroff DM, Heidger PM, Hendrix MJ. A novel immunological model for the study of prostate cancer. Cancer research. 1999;59(10):2271-6. Epub 1999/05/27. PubMed PMID: 10344727.
  100.  
  101. Luo J, Sharma N, Seftor EA, De Larco J, Heidger PM, Hendrix MJ, Lubaroff DM. Heterogeneous Expression of Invasive and Metastatic Properties in a Prostate Tumor Model. Pathology oncology research : POR. 1997;3(4):264-71. Epub 1997/01/01. PubMed PMID: 11173646.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

  • 1999-present         American Association for Cancer Research

AWARDS & HONORS

  • Phyllis and Brian L. Harvey Scholar, 2007

  • David H. Koch Foundation Award, 2006

  • Pathology Young Investigators' Day Award for Excellence in Basic Science Research, Department of Pathology, JHUSOM, 2002
  • Scholar-in-Training Award, American Association for Cancer Research, 2001
  • Young Investigator Award, American Association for Cancer Research, 1998
  • Tung-Yang Wing Award for Superior Achievement, Department of Anatomy and Cell Biology, University of Iowa, 1998

PATENTS

Jun Luo, Rong Hu, Thomas Dunn, William Isaacs, G.S. Bova. Composition and methods for treating and preventing prostate cancer and for detecting androgen receptor variants. JHTT Filing No.: P10305-02 (PCT).

Jun Luo, Rong Hu, Thomas Dunn, William Isaacs. Methods of detecting prostate cancer. U.S. Provisional Application No. 60/959,954 (PCT).

   CONTACT INFORMATION

 

  • Address:
    411 Marburg Building,
    600 N Wolf St.
    The Johns Hopkins Hospital
    Baltimore, MD 21287-2101
  • Office: 443-287-5625
  • Fax: 410-502-9336




© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287